medigraphic.com

2025, Number 1

<< Back Next >>

Rev Hematol Mex 2025; 26 (1)

Chronic myeloid leukemia: Clinical challenges in the treatment of tyrosine kinase inhibitor resistance and cardiovascular complications

García C, Luna R, Martínez T, Nájera J, Carrillo Á, Barranco G

Language: Spanish
References: 31
Page: 1-11
PDF size: 468.63 Kb.


ABSTRACT

BACKGROUND: Chronic myeloid leukemia prognosis has significantly improved with tyrosine kinase inhibitors. However, treatment resistance and cardiovascular complications remain challenges, especially in Latin America.
CLINICAL CASE: A 45-year-old male patient diagnosed with chronic-phase chronic myeloid leukemia carrying the T315I mutation, who was treated with ponatinib after loss of major molecular response on imatinib. The patient achieved a deep molecular response (MR4.5) but developed deep vein thrombosis, prompting temporary treatment suspension, anticoagulation, and dose adjustment. Therapy was resumed at 30 mg daily, maintaining response without recurrence.
CONCLUSIONS: This experience demonstrates that deep and sustained disease control is achievable through comprehensive management, balancing efficacy and safety. Such an approach is especially critical in Latin America, where challenges in access to treatment, timely diagnosis, and molecular follow-up persist.


REFERENCES

  1. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2025update on diagnosis, therapy, and monitoring. Am J Hematol 2024; 99 (11): 2191-212. https://doi.org.10.1002/ajh.27443

  2. Barranco G, Vidal I, Gama D, Martínez C, et al. Impact ofa guaranteed access program to imatinib on the survivalof patients with chronic myeloid leukemia. Cancer CausesControl 2024; 35 (12): 1557-63. https://doi.org/10.1007/s10552-024-01912-1

  3. Ayala M, Ávila E, Domínguez J, Aquino X, Vela J. Diagnosisand treatment of chronic myeloid leukemia in the imatinibmesylate era: Report of the experience at “La Raza” medicalcenter in Mexico. Clin Lymphoma Myeloma Leuk 2016;16 (2): 57-62. https://doi.org.10.1016/j.clml.2015.10.006

  4. Santoyo-Sánchez A, Ramos-Peñafiel CO, Saavedra-GonzálezA, González-Almanza L, et al. Frecuencias de edad y génerode pacientes con leucemia observada en dos centros dereferencia del Valle de México. Gac Med Mex 2016; 152(2): 208-12.

  5. Hu Y, Li Q, Hou M, Peng J, et al. Magnitude and temporaltrend of the chronic myeloid leukemia: On the basis ofthe global burden of disease study 2019. JCO Glob Oncol2021; 7: 1429-41. https://doi.org.10.1200/GO.21.00194

  6. International Agency for Research on Cancer. GLOBOCAN2022: Cancer registries list. Lyon: IARC. https://gco.iarc.who.int/media/globocan/material/GLOBOCAN2022_registries_list.pdf

  7. The age of Mexican patients with chronic myeloid leukemia(CML) Ph+ is quite younger than the reported in USA andEuropean series. Blood 2009; 114 (22): 4291. https://doi.org/10.1182/blood.V114.22.4291.4291

  8. McGarry LJ, Chen YJ, Divino V, Pokras S, et al. Increasingeconomic burden of tyrosine kinase inhibitor treatmentfailure by line of therapy in chronic myeloid leukemia. CurrMed Res Opin 2016; 32 (2): 289-99. https://doi.org.10.1185/03007995.2015.1120189

  9. McMullan RR, McConville C, McMullin MF. Responseto therapy, treatment intolerance and tyrosine kinaseinhibitor cessation eligibility in a real-world cohort ofchronic myeloid leukaemia patients. Ulster Med J 2019;88 (2): 105-10.

  10. Breccia M, Chiodi F, Nardozza AP, Valsecchi D, et al. Theeconomic burden of chronic myeloid leukemia in patientswith later lines: Findings from a real-world analysis in Italy.Adv Ther 2023; 40 (3): 961-75. https://doi.org.10.1007/s12325-022-02398-6

  11. Hochhaus A, Baccarani M, Silver RT, Schiffer C, et al. EuropeanLeukemiaNet 2020 recommendations for treatingchronic myeloid leukemia. Leukemia 2020; 34 (4): 966-84.https://doi.org.10.1038/s41375-020-0776-2

  12. Shah NP, Bhatia R, Altman JK, Amaya M, et al. Chronicmyeloid leukemia, version 2.2024, NCCN clinical practiceguidelines in oncology. J Natl Compr Canc Netw 2024; 22(1): 43-69. https://doi.org.10.6004/jnccn.2024.0007

  13. Jabbour E, Parikh SA, Kantarjian H, Cortes J. Chronic myeloidleukemia – mechanisms of resistance and treatment.Hematol Oncol Clin North Am 2011; 25 (5): 981-95. https://doi.org.10.1016/j.hoc.2011.09.004

  14. Quintás-Cardama A, Kantarjian HM, Cortes JE. Mechanismsof primary and secondary resistance to imatinib in chronicmyeloid leukemia. Cancer Control 2009; 16 (2): 122-31.https://doi.org.10.1177/107327480901600204

  15. Sun J, Hu R, Han M, Tan Y, et al. Mechanisms underlyingtherapeutic resistance of tyrosine kinase inhibitors in chronicmyeloid leukemia. Int J Biol Sci 2024; 20 (1): 175-85.https://doi.org.10.7150/ijbs.86305

  16. Marin D, Bazeos A, Mahon FX, Eliasson L, et al. Adherenceis the critical factor for achieving molecular responses inpatients with chronic myeloid leukemia who achieve completecytogenetic responses on imatinib. J Clin Oncol 2010;28 (14): 2381-8. https://doi.org.10.1200/JCO.2009.26.3087

  17. Cortes JE, Kantarjian H, Shah NP, Bixby D, et al. Ponatinibin refractory Philadelphia chromosome-positive leukemias.N Engl J Med 2012; 367 (22): 2075-88. https://doi.org.10.1056/NEJMoa1205127

  18. Sacha T, Szczepanek E. Management of ponatinib dosingin chronic myeloid leukemia patients. J Physiol Phar macol 2021; 72 (3): 309-16. https://doi.org.10.26402/jpp.2021.3.02

  19. Jabbour E, Apperley J, Cortes J, Rea D, et al. Dose modificationdynamics of ponatinib in patients with chronic-phasechronic myeloid leukemia (CP-CML) from the PACE andOPTIC trials. Leukemia 2024; 38 (3): 475-81. https://doi.org/10.1038/s41375-024-02159-0

  20. Caocci G, Mulas O, Capodanno I, Abruzzese E, et al. Lowlow-density lipoprotein (LDL), cholesterol and triglyceridesplasma levels are associated with reduced risk of arterialocclusive events in chronic myeloid leukemia patientstreated with ponatinib in the real-life. Blood Cancer J 2020;10 (6): 12-20. https://doi.org/10.1038/s41408-020-0333-2

  21. Cortes JE, Sasaki K, Kim DW, Hughes TP, et al. Asciminib monotherapyin patients with chronic-phase chronic myeloidleukemia with the T315I mutation after ≥1 prior tyrosine kinaseinhibitor: 2-year follow-up results. Leukemia 2024; 38(7): 1420-30. https://doi.org/10.1038/s41375-024-02278-8

  22. Hughes TP, Mauro MJ, Cortes JE, Minami H, et al. Asciminibin chronic myeloid leukemia after ABL kinase inhibitorfailure. N Engl J Med 2019; 381 (24): 2315-26. https://doi.org/10.1056/NEJMoa1902328

  23. Hochhaus A, Réa D, Boquimpani C, Minami Y, et al. Asciminibvs bosutinib in chronic-phase chronic myeloidleukemia previously treated with at least two tyrosinekinase inhibitors: longer-term follow-up of ASCEMBL.Leukemia 2023; 37 (3): 617-26. https://doi.org/10.1038/s41375-023-01829-9

  24. Xu LP, Xu ZL, Zhang XH, Chen H, et al. Allogeneic stem celltransplantation for patients with T315I BCR-ABL mutatedchronic myeloid leukemia. Biol Blood Marrow Transplant2016; 22 (6): 1080-86. https://doi.org/10.1016/j.bbmt.2016.03.012

  25. Nicolini FE, Basak GW, Kim DW, Olavarria E, et al. Overallsurvival with ponatinib versus allogeneic stem cell transplantationin Philadelphia chromosome-positive leukemiaswith the T315I mutation. Cancer 2017; 123 (15): 2875-80.https://doi.org/10.1002/cncr.30558

  26. Radich J. When to consider allogeneic transplantation inCML. Clin Lymphoma Myeloma Leuk 2016; 16 Suppl: S93-7.https://doi.org/10.1016/j.clml.2016.02.008

  27. Ilander M, Koskenvesa P, Hernesniemi S, Lion T, et al. Inductionof sustained deep molecular response in a patient withchronic-phase T315I-mutated chronic myeloid leukemiawith interferon-α monotherapy. Leuk Lymphoma 2014; 55(4): 945-7. https://doi.org/10.3109/10428194.2013.812788

  28. Zhou L, Shi H, Jiang S, Ruan C, Liu H. Deep molecularresponse by IFN-α and dasatinib combination in a patientwith T315I-mutated chronic myeloid leukemia. Pharmacogenomics2016; 17 (10): 1125-9. https://doi.org/10.2217/pgs-2016-0049

  29. Itonaga H, Tsushima H, Hata T, Matsuo E, et al. Successfultreatment of a chronic-phase T315I-mutated chronic myelogenousleukemia patient with a combination of imatiniband interferon-alfa. Int J Hematol 2012; 95 (2): 209-13.https://doi.org/10.1007/s12185-012-1005-1

  30. Ruggiu M, Oberkampf F, Ghez D, Cony-Makhoul P, et al.Azacytidine in combination with tyrosine kinase inhibitorsinduced durable responses in patients with advanced phasechronic myelogenous leukemia. Leuk Lymphoma 2018; 59 (7):1528-35. https://doi.org/10.1080/10428194.2017.1397666

  31. Alves R, Gonçalves AC, Rutella S, Almeida AM, et al. Resistanceto tyrosine kinase inhibitors in chronic myeloidleukemia—From molecular mechanisms to clinical relevance.Cancers (Basel) 2021; 13 (19): 4820. https://doi.org/10.3390/cancers13194820




2020     |     www.medigraphic.com